JPH11302155A - Skin external preparation for atopic dermatitis - Google Patents
Skin external preparation for atopic dermatitisInfo
- Publication number
- JPH11302155A JPH11302155A JP10115396A JP11539698A JPH11302155A JP H11302155 A JPH11302155 A JP H11302155A JP 10115396 A JP10115396 A JP 10115396A JP 11539698 A JP11539698 A JP 11539698A JP H11302155 A JPH11302155 A JP H11302155A
- Authority
- JP
- Japan
- Prior art keywords
- ceramide
- external preparation
- atopic dermatitis
- skin
- moisturizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 10
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 10
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 20
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 20
- 229940106189 ceramide Drugs 0.000 claims abstract description 20
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 20
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002502 liposome Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 7
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000003020 moisturizing effect Effects 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
- 241001135917 Vitellaria paradoxa Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057910 shea butter Drugs 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- -1 cholesteryl ester Chemical class 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000008132 rose water Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- GBGUSZWBYGKEBA-VBYMIUBRSA-N (2R)-2-hydroxy-N-[(E,2S,3R,6R)-1,3,6-trihydroxyoctadec-4-en-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@@H](CO)[C@H](O)\C=C\[C@H](O)CCCCCCCCCCCC GBGUSZWBYGKEBA-VBYMIUBRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- WAYLDHLWVYQNSQ-KEFDUYNTSA-N N-2-hydroxylignoceroylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC WAYLDHLWVYQNSQ-KEFDUYNTSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明はアトピー性皮膚炎の
ための皮膚外用剤、さらに詳しくは、化粧料、医薬品等
として使用されるアトピー性皮膚炎のための皮膚外用剤
に関する。TECHNICAL FIELD The present invention relates to a skin external preparation for atopic dermatitis, and more particularly to a skin external preparation for atopic dermatitis used as cosmetics, pharmaceuticals and the like.
【０００２】[0002]
【従来の技術】周知のように、アトピー性皮膚炎は、ア
レルギー性，内因性の皮膚疾患で、痒み、炎症の他、角
化不全、乾燥肌等の症状を示し、患者も年々増加する傾
向にある。2. Description of the Related Art As is well known, atopic dermatitis is an allergic or endogenous skin disease that presents symptoms such as itching, inflammation, keratinization and dry skin, and the number of patients is increasing year by year. It is in.
【０００３】[0003]
【発明が解決しようとする課題】しかし、原因や発生の
メカニズムに不明な点が多く、短期的には治癒し難いも
のと認められている。However, there are many unclear points in the cause and the mechanism of occurrence, and it is recognized that it is difficult to heal in the short term.
【０００４】痒みを緩和する対処療法として、ステロイ
ド剤の投与等もなされているが、副作用を伴うという問
題点がある。[0004] As a coping therapy for relieving itching, administration of steroids or the like has been performed, but there is a problem that side effects are involved.
【０００５】本発明は、このような問題点を解決するた
めになされたもので、アトピー性皮膚炎の痒み、炎症等
の諸症状を緩和することができ、しかも副作用を生じさ
せないアトピー性皮膚炎のための皮膚外用剤を提供する
ことを課題とするものである。The present invention has been made in order to solve such problems, and can alleviate various symptoms such as itching and inflammation of atopic dermatitis, and also have no side effects. It is an object to provide a skin external preparation for skin care.
【０００６】[0006]
【課題を解決するための手段】本発明は、このような課
題を解決せんとするもので、その課題を解決するための
手段は、セラミドと、リポソームを形成しうる成分を含
有するゲル基剤とを配合したことにある。Means for Solving the Problems The present invention is intended to solve such problems, and a means for solving the problems is a gel base containing ceramide and a component capable of forming liposomes. And that it is blended.
【０００７】[0007]
【作用】アトピー性皮膚炎は、皮膚の保湿機能の低下に
よって生じ、より詳細には、皮表に存在するセラミド等
の脂質成分の減少がその原因であると考えられるが、上
記のようなセラミドを配合した外用剤を皮膚に投与する
ことによって、皮表に存在するセラミド等の脂質成分の
減少が阻止されることとなるのである。Atopic dermatitis is caused by a decrease in the moisturizing function of the skin. More specifically, it is thought that the cause is a decrease in lipid components such as ceramide present on the skin surface. By administering to the skin an external preparation containing, a decrease in lipid components such as ceramide present on the skin surface is prevented.
【０００８】[0008]
【実施例】以下、本発明の実施例について説明する。Embodiments of the present invention will be described below.
【０００９】一実施例としての皮膚外用剤の組成は、次
のとおりである。The composition of an external preparation for skin as one embodiment is as follows.
【００１０】 種別 配合成分 重量％ 基剤 グリセロール ８％ 1,3 −ブチレングリコール ７％ ジグリセリン ７％ トリグリセリド ８％ ２−エチルヘキ酸セチル ５％ スクワラン（天然種子由来スクワラン） ８％ 大豆リゾリン脂質液 ７％ 水素添加大豆リン脂質 ６％ シア脂 ５％ 保湿成分 エルデュウ（コレステリルエステル） ４％ セラミド ５％ ビサボロール ３％ ベタイン ３％ カミツレエキス ２％ ローズ水 ３％ アラントイン ２％ 天然ビタミンＥ ２％ β−グリチルレチン酸 ３％ グリチルレチン酸ステアリル １％ アスパラサスリネアリス １％ 保存剤 パラベン ５％ フェノキシエタノール ５％Type Ingredients Weight% Base Glycerol 8% 1,3-butylene glycol 7% Diglycerin 7% Triglyceride 8% Cetyl 2-ethylhexate 5% Squalane (natural seed-derived squalane) 8% Soybean lysophospholipid liquid 7% Hydrogenated soybean phospholipid 6% Shea butter 5% Moisturizing ingredient Eldow (cholesteryl ester) 4% Ceramide 5% Bisabolol 3% Betaine 3% Chamomile extract 2% Rose water 3% Allantoin 2% Natural vitamin E 2% β-glycyrrhetinic acid 3 % Stearyl glycyrrhetinate 1% Asparasas linealis 1% Preservatives Paraben 5% Phenoxyethanol 5%
【００１１】上記配合成分中、セラミドとしては、ビオ
セラミドＬＳ（商品名：山川貿易株式会社製）を使用し
た。In the above ingredients, Bioceramide LS (trade name: manufactured by Yamakawa Trading Co., Ltd.) was used as ceramide.
【００１２】このビオセラミドＬＳの組成は、次のとお
りである。The composition of this bioceramide LS is as follows.
【００１３】 配合成分 重量％ ガラクトシルセラミド（スフィンゴ糖脂質） ７０％ スフィンゴミエリン（スフィンゴリン脂質） １０％ ホスファチジルエタノールアミン（グリセロリン脂質） ９％ レシチン（グリセロリン脂質） ９％ コレステロール ２％Ingredients% by weight galactosylceramide (glycosphingolipid) 70% sphingomyelin (sphingolipid) 10% phosphatidylethanolamine (glycerophospholipid) 9% lecithin (glycerophospholipid) 9% cholesterol 2%
【００１４】また、上記皮膚外用剤中の基剤において、
グリセロール、1,3 −ブチレングリコール、トリグリセ
リド、２−エチルヘキ酸セチルは、保湿を目的として配
合されたものであり、ジグリセリンは、保湿の他にベタ
ツキ低減を目的として配合されたものであり、大豆リゾ
リン脂質液及び水素添加大豆リン脂質は保湿の他にリポ
ソームを形成する機能を有するために配合させるもので
あり、シア脂は保湿の他に紫外線保護のために配合され
るものであり、スクワランは皮脂類似成分として配合さ
れるものである。[0014] Further, in the base in the above external preparation for skin,
Glycerol, 1,3-butylene glycol, triglyceride and cetyl 2-ethylhexate were formulated for moisturizing, and diglycerin was formulated for moisturizing and reducing stickiness. The lysophospholipid liquid and the hydrogenated soybean phospholipid are blended to have a function of forming liposomes in addition to moisturizing, and the shea butter is blended for UV protection in addition to moisturizing. It is blended as a sebum-like component.
【００１５】一方、上記皮膚外用剤中の保湿成分におい
て、セラミドとベタインは保湿自体を目的とするもので
あるが、エルデュウは保湿の他にリポソームを形成する
機能を具備させるために配合させるものであり、カミツ
レエキスは保湿の他にマスキングを目的として配合され
るものであり、アスパラサスリネアリスは保湿の他にＳ
ＯＤ様にすることを目的として配合されるものであり、
ローズ水はマスキングのために配合されるものであり、
ビサボロールは抗菌，消炎のために配合されるものであ
り、アラントインは消炎のために配合されるものであ
り、β−グリチルレチン酸とグリチルレチン酸ステアリ
ルは消炎，抗アレルギーのために配合されるものであ
り、天然ビタミンＥは抗酸化のために配合されるもので
ある。On the other hand, among the moisturizing components in the above-mentioned external preparation for skin, ceramide and betaine are used for the purpose of moisturizing themselves, while Eldew is added to have a function of forming liposomes in addition to moisturizing. Yes, chamomile extract is formulated for the purpose of masking in addition to moisturizing, and Asparasas linealis is S
It is formulated for the purpose of making it OD-like,
Rose water is formulated for masking,
Bisabolol is formulated for antimicrobial and anti-inflammatory, allantoin is formulated for anti-inflammatory, β-glycyrrhetinic acid and stearyl glycyrrhetinate are formulated for anti-inflammatory and anti-allergic. Natural vitamin E is used for antioxidation.
【００１６】さらに、パラベンやフェノキシエタノール
は防腐のために配合されるものである。Furthermore, paraben and phenoxyethanol are blended for preservation.
【００１７】上記実施例の皮膚外用剤は、保湿を目的と
する主成分であるセラミドが配合されているため、皮表
に存在するセラミド等の脂質成分を補填することがで
き、その結果、セラミドの減少を防いで保湿効果を維持
することができる。Since the external preparation for skin of the above embodiment contains ceramide, which is a main component for moisturizing, it can supplement lipid components such as ceramide present on the skin surface. And the moisture retention effect can be maintained.
【００１８】また、セラミド以外にも、各種の保湿成分
が配合されており、さらに基剤の中にも保湿を目的とす
る成分が配合されているため、全体としての保湿効果が
非常に優れたものになるという効果がある。In addition, various moisturizing components other than ceramide are compounded, and the component for moisturizing is also compounded in the base, so that the moisturizing effect as a whole is very excellent. It has the effect of becoming something.
【００１９】さらに、基剤中に、リポソームを形成しう
る大豆リゾリン脂質液及び水素添加大豆リン脂質が配合
されているため、このリポソームが界面活性剤として機
能し、セラミド等の保湿成分が基剤に好適に混合される
こととなる。Further, since the soybean lysophospholipid solution capable of forming liposomes and the hydrogenated soybean phospholipid are blended in the base, the liposomes function as a surfactant, and a humectant such as ceramide is used as the base. Will be suitably mixed.
【００２０】上記実施例の皮膚外用剤についてモニター
患者90人に対して臨床試験を行った。A clinical test was conducted on 90 externally monitored patients using the skin external preparations of the above examples.
【００２１】その結果を表１乃至表３に示す。The results are shown in Tables 1 to 3.
【００２２】[0022]
【表１】 [Table 1]
【００２３】[0023]
【表２】 [Table 2]
【００２４】[0024]
【表３】 [Table 3]
【００２５】表１乃至表３からも明らかなように、多く
のモニター患者に対して改善の程度は良好なものであっ
た。As is clear from Tables 1 to 3, the degree of improvement was good for many monitor patients.
【００２６】尚、皮膚外用剤に配合される成分と重量％
は上記実施例に限定されるものではない。[0026] In addition, the ingredients and the weight%
Is not limited to the above embodiment.
【００２７】たとえば、次のような配合成分のものも使
用される。 種別 配合成分 重量％ 基剤 トリグリセリド １８％ 大豆リゾリン脂質液 １６％ 水素添加大豆リン脂質 １６％ シア脂 １５％ 保湿成分 エルデュウ（コレステリルエステル） ８％ セラミド ７％ ベタイン ７％ β−グリチルレチン酸 ７％ グリチルレチン酸ステアリル ６％For example, the following components are also used. Type Ingredients Weight% Base Triglyceride 18% Soybean lysophospholipid liquid 16% Hydrogenated soybean phospholipid 16% Shea butter 15% Moisturizing ingredient Eldeu (cholesteryl ester) 8% Ceramide 7% Betaine 7% β-Glycyrrhetinic acid 7% Glycyrrhetinic acid Stearyl 6%
【００２８】要は、ゲル基剤とセラミドが配合されてい
ればよく、ゲル基剤中にリポソームを形成しうる成分が
配合されていればよい。In short, it is only necessary that the gel base and the ceramide are blended, and it is sufficient that the gel base contains a component capable of forming liposomes.
【００２９】従って、他の成分を配合することは条件で
はなく、その成分は任意に変更しうる。Therefore, it is not a condition to mix other components, and the components can be arbitrarily changed.
【００３０】さらに、上記実施例では、セラミドとして
上記配合成分からなるビオセラミドＬＳを用いたが、セ
ラミドの種類はこれに限定されるものではなく、たとえ
ばセラミドIII （商品名）〔一般名はＮ−ステアロイル
フィトスフィインゴシン〕を使用することも可能であ
り、またグリコセラミド等を使用することも可能であ
る。Further, in the above-mentioned embodiment, bioceramide LS composed of the above-mentioned components was used as ceramide. However, the type of ceramide is not limited to this, and for example, ceramide III (trade name) [generic name is N- Stearoyl phytosphingosin], and glycoceramide or the like can also be used.
【００３１】さらに、本発明の皮膚外用剤の用途も、化
粧料の他、医薬品に使用することも可能であり、その用
途は問わない。Further, the use of the external preparation for skin of the present invention can be used not only for cosmetics but also for pharmaceuticals, and its use is not limited.
【００３２】[0032]
【発明の効果】叙上のように、本発明は、皮膚外用剤中
にセラミドと、リポソームを含有するゲル基剤とを配合
したものであるため、このような皮膚外用剤を投与すれ
ば、配合成分であるセラミドが皮表に補填されることと
なる。As described above, according to the present invention, a ceramide and a liposome-containing gel base are blended in an external preparation for skin. Ceramide, which is a compounding component, is supplemented to the skin surface.
【００３３】従って、アトピー性皮膚炎が発症すると、
一般には皮表に存在するセラミド等が減少するが、上記
のような配合成分であるセラミドが補填されることによ
って皮表に存在する脂質成分の減少が阻止されることと
なり、それによってアトピー性皮膚炎の症状を緩和する
ことができるという効果がある。Therefore, when atopic dermatitis develops,
In general, ceramide and the like present on the skin surface are reduced, but the reduction of lipid components present on the skin surface is prevented by supplementing the ceramide which is a compounding component as described above, whereby atopic skin is reduced. It has the effect of alleviating the symptoms of flame.
【００３４】また、セラミド自体が一般には生体内で代
謝されうる物質であるため、ステロイド剤のように副作
用を生ずるおそれも少ないという利点がある。In addition, since ceramide itself is generally a substance that can be metabolized in a living body, there is an advantage that there is little possibility of causing side effects unlike steroids.
【００３５】さらに、基剤がゲル状の基剤であるため、
患部に好適に塗布することができる他、痒みに起因する
掻き傷等が患部に存在しても、刺激を与えないという利
点がある。Further, since the base is a gel base,
In addition to being able to be suitably applied to the affected area, there is an advantage that no irritation is given even if a scratch or the like due to itch is present in the affected area.
【００３６】また、基剤中に、リポソームを形成しうる
成分が配合されているため、このリポソームが界面活性
剤として機能し、セラミド等の保湿成分が基剤に好適に
混合されるという効果がある。Further, since a component capable of forming a liposome is blended in the base, the liposome functions as a surfactant, and has an effect that a moisturizing component such as ceramide is suitably mixed with the base. is there.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ａ６１Ｋ 31/16 ＡＤＡ Ａ６１Ｋ 31/16 ＡＤＡ ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 31/16 ADA A61K 31/16 ADA
Claims (1)
分を含有するゲル基剤とを配合したことを特徴とするア
トピー性皮膚炎のための皮膚外用剤。1. A skin external preparation for atopic dermatitis, comprising a mixture of ceramide and a gel base containing a component capable of forming liposomes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10115396A JPH11302155A (en) | 1998-04-24 | 1998-04-24 | Skin external preparation for atopic dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10115396A JPH11302155A (en) | 1998-04-24 | 1998-04-24 | Skin external preparation for atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11302155A true JPH11302155A (en) | 1999-11-02 |
Family
ID=14661533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10115396A Pending JPH11302155A (en) | 1998-04-24 | 1998-04-24 | Skin external preparation for atopic dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH11302155A (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002003378A (en) * | 2000-06-22 | 2002-01-09 | Kanebo Ltd | External antipruritic agent |
| WO2002076401A2 (en) | 2001-03-26 | 2002-10-03 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| KR20020076375A (en) * | 2001-03-28 | 2002-10-11 | (주)바이오랩 | Cosmetics Useful for atopic skin |
| JP2003095926A (en) * | 2001-09-26 | 2003-04-03 | Nof Corp | Fatty acid-containing liposome dispersion |
| JP2003155231A (en) * | 2001-11-20 | 2003-05-27 | Kikkoman Corp | Medicine and antiallergic agent |
| JP2005314254A (en) * | 2004-04-28 | 2005-11-10 | Pola Chem Ind Inc | External preparation for skin which is suitable as quasi-drug |
| JPWO2004009041A1 (en) * | 2002-07-22 | 2005-12-08 | 辻製油株式会社 | Skin cosmetic composition |
| WO2005120574A1 (en) * | 2004-06-11 | 2005-12-22 | Riken | Drug having regulatory cell ligand contained in liposome |
| KR100539965B1 (en) * | 2002-08-29 | 2006-01-10 | 주식회사 코리아나화장품 | Cosmetic composition for the prevention and alleviation of atopic dermatitis comprising a novel pseudo ceramide |
| WO2006067875A1 (en) * | 2004-12-22 | 2006-06-29 | Yamachu Co., Ltd. | Anti-uv aqueous cosmetic composition |
| KR100747502B1 (en) * | 2006-03-23 | 2007-08-08 | (주)더페이스샵코리아 | Skin irritation complex and cosmetic composition containing the same |
| JP2007246407A (en) * | 2006-03-14 | 2007-09-27 | Noevir Co Ltd | Anti-staphylococcus aureus agent |
| JP2008127327A (en) * | 2006-11-20 | 2008-06-05 | Ands Corporation | Nanoemulsion and cosmetics containing the same |
| KR100858626B1 (en) | 2006-07-31 | 2008-09-17 | 주식회사 코리아나화장품 | Cosmetic composition for lip protection containing ceramide and synthetic palmitoylpentapeptide as active ingredients |
| JP2009514806A (en) * | 2005-10-11 | 2009-04-09 | ユニバーシティー オブ ピッツバーグ | Sphingomyelin liposomes for the treatment of overactive bladder disorders |
| JP2010043027A (en) * | 2008-08-13 | 2010-02-25 | Kracie Home Products Ltd | Oil-in-water type emulsified cosmetic |
| JP2013224290A (en) * | 2012-03-22 | 2013-10-31 | Fujifilm Corp | Highly transparent emulsion composition and highly transparent cosmetic |
| JP2016094363A (en) * | 2014-11-13 | 2016-05-26 | ポーラ化成工業株式会社 | Liquid crystal emulsion composition |
| CN114668685A (en) * | 2020-12-24 | 2022-06-28 | Naos生命科学研究所 | Cosmetic composition capable of strengthening epidermal tight junctions to prevent and/or treat atopic dermatitis |
-
1998
- 1998-04-24 JP JP10115396A patent/JPH11302155A/en active Pending
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002003378A (en) * | 2000-06-22 | 2002-01-09 | Kanebo Ltd | External antipruritic agent |
| US7419958B2 (en) | 2001-03-26 | 2008-09-02 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| WO2002076401A2 (en) | 2001-03-26 | 2002-10-03 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US10226476B2 (en) | 2001-03-26 | 2019-03-12 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| EP1372668A4 (en) * | 2001-03-26 | 2007-07-25 | Dana Farber Cancer Inst Inc | METHOD OF DEHUMIDIFYING REACTIONS ON SKIN-RELIEFING AGENTS |
| KR20020076375A (en) * | 2001-03-28 | 2002-10-11 | (주)바이오랩 | Cosmetics Useful for atopic skin |
| JP2003095926A (en) * | 2001-09-26 | 2003-04-03 | Nof Corp | Fatty acid-containing liposome dispersion |
| JP2003155231A (en) * | 2001-11-20 | 2003-05-27 | Kikkoman Corp | Medicine and antiallergic agent |
| JPWO2004009041A1 (en) * | 2002-07-22 | 2005-12-08 | 辻製油株式会社 | Skin cosmetic composition |
| KR100539965B1 (en) * | 2002-08-29 | 2006-01-10 | 주식회사 코리아나화장품 | Cosmetic composition for the prevention and alleviation of atopic dermatitis comprising a novel pseudo ceramide |
| JP2005314254A (en) * | 2004-04-28 | 2005-11-10 | Pola Chem Ind Inc | External preparation for skin which is suitable as quasi-drug |
| AU2005251589B2 (en) * | 2004-06-11 | 2011-01-06 | Riken | Drug having regulatory cell ligand contained in liposome |
| US8920774B2 (en) | 2004-06-11 | 2014-12-30 | Riken | Drug having regulatory cell ligand contained in liposome |
| WO2005120574A1 (en) * | 2004-06-11 | 2005-12-22 | Riken | Drug having regulatory cell ligand contained in liposome |
| US9387170B2 (en) | 2004-06-11 | 2016-07-12 | Riken | Drug having regulatory cell ligand contained in liposome |
| JP4889485B2 (en) * | 2004-06-11 | 2012-03-07 | 独立行政法人理化学研究所 | Drug comprising regulatory cell ligand in liposome |
| CN1997395B (en) | 2004-06-11 | 2012-08-29 | 独立行政法人理化学研究所 | Drugs containing regulatory cell ligands contained in liposomes |
| WO2006067875A1 (en) * | 2004-12-22 | 2006-06-29 | Yamachu Co., Ltd. | Anti-uv aqueous cosmetic composition |
| JP2009514806A (en) * | 2005-10-11 | 2009-04-09 | ユニバーシティー オブ ピッツバーグ | Sphingomyelin liposomes for the treatment of overactive bladder disorders |
| JP2007246407A (en) * | 2006-03-14 | 2007-09-27 | Noevir Co Ltd | Anti-staphylococcus aureus agent |
| KR100747502B1 (en) * | 2006-03-23 | 2007-08-08 | (주)더페이스샵코리아 | Skin irritation complex and cosmetic composition containing the same |
| KR100858626B1 (en) | 2006-07-31 | 2008-09-17 | 주식회사 코리아나화장품 | Cosmetic composition for lip protection containing ceramide and synthetic palmitoylpentapeptide as active ingredients |
| JP2008127327A (en) * | 2006-11-20 | 2008-06-05 | Ands Corporation | Nanoemulsion and cosmetics containing the same |
| JP2010043027A (en) * | 2008-08-13 | 2010-02-25 | Kracie Home Products Ltd | Oil-in-water type emulsified cosmetic |
| JP2013224290A (en) * | 2012-03-22 | 2013-10-31 | Fujifilm Corp | Highly transparent emulsion composition and highly transparent cosmetic |
| JP2016094363A (en) * | 2014-11-13 | 2016-05-26 | ポーラ化成工業株式会社 | Liquid crystal emulsion composition |
| CN114668685A (en) * | 2020-12-24 | 2022-06-28 | Naos生命科学研究所 | Cosmetic composition capable of strengthening epidermal tight junctions to prevent and/or treat atopic dermatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11302155A (en) | Skin external preparation for atopic dermatitis | |
| US4610978A (en) | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same | |
| US20100222305A1 (en) | Complexes of phosphate derivatives | |
| US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
| JPS63275506A (en) | Skin cosmetic | |
| EP1069886B1 (en) | Use of a topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, for providing a prolonged effect of an incorporated active substance | |
| USRE33107E (en) | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same | |
| US3867522A (en) | Acne composition | |
| EP2566455B1 (en) | Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies | |
| WO2008013669A2 (en) | Alpha hydroxy acid sustained release formulation | |
| JP2003128531A (en) | Dermal external agent | |
| JP2002161027A (en) | Methods and compositions for reducing inflammation and erythema | |
| CN112716823A (en) | High-moisture-retention moisture gel cream and preparation method thereof | |
| EP0747040A1 (en) | Petroleum jelly with inositol phosphates | |
| KR100888752B1 (en) | External dermal agent | |
| JP2003081741A (en) | Skin care preparation | |
| JPH08133948A (en) | Skin preparation for external use | |
| JP2011241228A (en) | Skin preparation for external use | |
| JPH0899854A (en) | Skin external agent | |
| US20250319104A1 (en) | Moisturizing cream for radiation dermatitis | |
| JP6209350B2 (en) | Acne control composition, external preparation for skin and cosmetics | |
| JPH08268866A (en) | Dermal preparation for external use | |
| KR20210059385A (en) | Cosmetic composition comprising complex for alleviating skin irritation with lamella liquid crystal structure | |
| JPH08165244A (en) | Skin disease treatment | |
| JP2826141B2 (en) | Dandruff inhibitor composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |